Nilotinib (AMN-107)

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nilotinib (AMN-107) Chemical Structure

Nilotinib (AMN-107) Chemical Structure
Molecular Weight: 529.52

Validation & Quality Control

Customer Product Validation(5)

Quality Control & MSDS

Related Compound Libraries

Bcr-Abl Inhibitors with Unique Features

  • Pan Bcr-Abl Inhibitor

    Imatinib Mesylate (STI571) Multi-target inhibitor of v-Abl, c-Kit and PDGFRIC50=0.6 μM/0.1 μM/0.1 μM.

  • Most Potent Bcr-Abl Inhibitor

    GZD824 Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.

  • FDA-approved Bcr-Abl Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Bcr-Abl Inhibitor

    GZD824 Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Product Information

  • Compare Bcr-Abl Inhibitors
    Compare Bcr-Abl Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Targets Bcr-Abl [1]
(Murine myeloid progenitor cells)
IC50 <30 nM
In vitro Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellNWDaTYVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLoN5ZKSzVyPUCuNFAxOTR2IN88US=>NGfGT2pUSU6JRWK=
KU812NFTHPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjZWZltUUN3ME2wMlAxOjR6IN88US=>MlrWV2FPT0WU
EM-2MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEGwSnNKSzVyPUCuNFA1OSEQvF2=M1\LOXNCVkeHUh?=
LAMA-84NEO1XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXVemQyUUN3ME2wMlAxPDlizszNNFjCN2lUSU6JRWK=
MEG-01M2P5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfITWM2OD1yLkCwPFI5KM7:TR?=MUHTRW5ITVJ?
BV-173NYfXXXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHpfWJxUUN3ME2wMlAyODh7IN88US=>M4rMe3NCVkeHUh?=
KASUMI-1NYrkOFZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DDc2lEPTB;MD6wNlQyOyEQvF2=MnTWV2FPT0WU
NB7MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTBwMUO0N|kh|ryPNUPw[pZkW0GQR1XS
BHT-101MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITxRYdKSzVyPUCuOlQzPjNizszNMVHTRW5ITVJ?
CGTH-W-1M1TISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnv1TWM2OD1yLk[0PFch|ryPNHu5SVVUSU6JRWK=
HMV-IINETsWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnrT4pKSzVyPUCuO|Q5PzRizszNMn3uV2FPT0WU
NKM-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XVc2lEPTB;MD65NFE2KM7:TR?=NFfzc|dUSU6JRWK=
LB2241-RCCNUDZU4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDFTWM2OD1zLkCyNlI5KM7:TR?=NYPUeXQzW0GQR1XS
NCI-H1703M2m3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTFwMUi4O{DPxE1?NVnkdFVyW0GQR1XS
BE-13NULPOnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTFwMke0NVYh|ryPM{\iXnNCVkeHUh?=
ACNMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzZTWM2OD1zLkW1NFc4KM7:TR?=M3j6THNCVkeHUh?=
A204M2X6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnxeIVKSzVyPUGuOVczODVizszNMXjTRW5ITVJ?
HOP-62MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTFwOEKwO|ch|ryPM1zsdHNCVkeHUh?=
H9MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJwN{O3PVMh|ryPMULTRW5ITVJ?
HCC1806NXXCW|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHScmRKSzVyPUKuO|Q{OjdizszNNIPHe|ZUSU6JRWK=
NOS-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nRV2lEPTB;Mj64O|ExOiEQvF2=NIe0Wo9USU6JRWK=
RS4-11NHT5bYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJwOUC2NlMh|ryPMXrTRW5ITVJ?
JARMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\1XpFCUUN3ME2yMlkzODh2IN88US=>NX7NSGhuW0GQR1XS
T98GNVGxPGRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jhTWlEPTB;Mz6wNVMyOyEQvF2=MWLTRW5ITVJ?
NCI-SNU-1NYTHVmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTNwNECwPVIh|ryPMXLTRW5ITVJ?
SK-MEL-1NFLBV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[5bZFKSzVyPUOuOFMxOjlizszNM4XUeXNCVkeHUh?=
L-363NYqyZ|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2H5WWlEPTB;Mz62NVExPyEQvF2=M2Wx[3NCVkeHUh?=
SW982MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTNwNkSxOlkh|ryPM{PvPXNCVkeHUh?=
HT-1080MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWroVW5lUUN3ME2zMlkyPzd3IN88US=>Mke4V2FPT0WU
G-402NYDqTWx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTRwM{GyNFMh|ryPM4\ZXXNCVkeHUh?=
HOSMor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDvTWM2OD12LkiwNlgzKM7:TR?=NVjqOY5CW0GQR1XS
SK-NEP-1MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HNNWlEPTB;ND64N|E6OSEQvF2=M4rKeHNCVkeHUh?=
HAL-01NXnienFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTRwOEiyOFIh|ryPM1vXNnNCVkeHUh?=
SBC-1MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULkN2xkUUN3ME20MlkxQTB5IN88US=>MWnTRW5ITVJ?
CTV-1NE\MbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfS[ndKSzVyPUWuOFg6OzhizszNMWLTRW5ITVJ?
LCLC-103HNG\6dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTVwN{e0O|Eh|ryPNXL0WXpWW0GQR1XS
RVH-421MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XJZmlEPTB;NT63O|U{PiEQvF2=M2i0VnNCVkeHUh?=
K-562M2rmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Pm[WlEPTB;NT65NFM3KM7:TR?=NXjQeWE3W0GQR1XS
CAL-33MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTZwM{GzOVkh|ryPMXnTRW5ITVJ?
MDA-MB-361NIe1fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfZTWM2OD14LkOzOlk6KM7:TR?=NV7rOotzW0GQR1XS
IGROV-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTZwNEexPVEh|ryPMl\RV2FPT0WU
NYNEKwWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnG0TWM2OD14LkWzOVk6KM7:TR?=NGfhV5hUSU6JRWK=
Ramos-2G6-4C10NEToWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTZwNk[5N|Eh|ryPMmjGV2FPT0WU
HuO9M1\Zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2K2dGlEPTB;Nj63N|k3PCEQvF2=M1XZOXNCVkeHUh?=
MS-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojKTWM2OD15LkGxPVU{KM7:TR?=NVLqN2NrW0GQR1XS
RPMI-8226MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fkW2lEPTB;Nz6yPFI5PyEQvF2=NXfK[4U4W0GQR1XS
HDLM-2MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\JTWM2OD15LkSwNVQ6KM7:TR?=M13wNXNCVkeHUh?=
D-566MGMn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnlTWM2OD15LkS3NVU2KM7:TR?=NVWyR2J6W0GQR1XS
SK-MEL-24MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXS3fHBrUUN3ME23MlY{Ozl{IN88US=>NYPTTnRqW0GQR1XS
COLO-679MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTdwOUi2O|Eh|ryPMl2zV2FPT0WU
EW-13Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXBe2IyUUN3ME24MlMzODV2IN88US=>MnT2V2FPT0WU
A388MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRThwM{i0PFEh|ryPMV\TRW5ITVJ?
UM-UC-3NWTIN5dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRThwNEO5OVYh|ryPMUTTRW5ITVJ?
NUGC-3MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDMTWM2OD16LkWzOVgzKM7:TR?=NVu0enhsW0GQR1XS
COLO-668MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLQblU1UUN3ME24MlU6PDlzIN88US=>MoDzV2FPT0WU
MOLT-4NW\WfZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHWTWM2OD16Lk[yN|U{KM7:TR?=M1TvUnNCVkeHUh?=
D-423MGM2DqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\TU2lEPTB;OD64N|c2PiEQvF2=M2O3NnNCVkeHUh?=
CTB-1MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRThwOEexNlgh|ryPMWDTRW5ITVJ?
BCPAPMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fuPGlEPTB;OT6wNlU3OiEQvF2=NFTMW3hUSU6JRWK=
GCTNG[3OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkmwTWM2OD17LkC5PFMyKM7:TR?=M3HsfXNCVkeHUh?=
ACHNM{TtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS3TWM2OD17LkKzOlMzKM7:TR?=M2DHcHNCVkeHUh?=
KYSE-520NWCze4tCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;6[ZF[UUN3ME25MlM{PDh{IN88US=>NWjx[ot[W0GQR1XS
LB771-HNCMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHyTWM2OD17Lke2OFk4KM7:TR?=NVjBOmp1W0GQR1XS
MLMANFLVc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4GzS2lEPTB;MUCuNFE{OiEQvF2=NUXORo51W0GQR1XS
HEC-1M4[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXkeZd4UUN3ME2xNE4zQDB2IN88US=>MV3TRW5ITVJ?
HL-60NX3QUWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUf6UWRPUUN3ME2xNE43QDV|IN88US=>MXzTRW5ITVJ?
A101DNYTacIRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXtTWM2OD1zMD64PVI{KM7:TR?=NFjPWo1USU6JRWK=
A2058NF;VOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzUdFQ2UUN3ME2xNE46OjR3IN88US=>NEfwZppUSU6JRWK=
KARPAS-45NHjOXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fFd2lEPTB;MUGuNFY{PSEQvF2=MXzTRW5ITVJ?
697NEH0[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTFzLkKxNFEh|ryPMnjmV2FPT0WU
NCI-N87NFLnVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NID4ZWNKSzVyPUGxMlc4OzFizszNM4nYUnNCVkeHUh?=
DSH1NIS4S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoX0TWM2OD1zMT63PVU{KM7:TR?=MUTTRW5ITVJ?
HLENEDq[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfaTWM2OD1zMT64PFM6KM7:TR?=NEHZWZdUSU6JRWK=
NCI-H720MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHtNFQ1UUN3ME2xNk43QDBzIN88US=>MmTDV2FPT0WU
EW-3NVPSVpFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVmwNZRjUUN3ME2xNk46OzB5IN88US=>M2jySnNCVkeHUh?=
AGSMlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVv5e3ZnUUN3ME2xN{4xOzVzIN88US=>NF63cGhUSU6JRWK=
ES5MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP5c5VKSzVyPUGzMlA2OTJizszNNVHBU5NnW0GQR1XS
DBNEjZN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\4TWM2OD1zMz6zNlU3KM7:TR?=NEXyRZVUSU6JRWK=
A4-FukM4LmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF|LkSxNFIh|ryPMULTRW5ITVJ?
A427NEGwVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTF|LkS5O|Ih|ryPNXPYPVBYW0GQR1XS
MN-60MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXNcYFKSzVyPUGzMlU5PDNizszNMmnYV2FPT0WU
HCC2218MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDaV|RKSzVyPUGzMlU5PTZizszNNX;DVJF7W0GQR1XS
MV-4-11M3\JN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF|LkixN|ch|ryPNHTIeJRUSU6JRWK=
GI-1M1LD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLZVoFKSzVyPUG0MlEyQDRizszNMWrTRW5ITVJ?
JVM-3M3rGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;TPYZKSzVyPUG0MlI3PTZizszNM{LLV3NCVkeHUh?=
NCI-H2029MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTF2LkK3Nlch|ryPNXLXRVNlW0GQR1XS
TE-12MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLTU45KSzVyPUG0MlYxPDZizszNMnnuV2FPT0WU
WM-115NXfHTYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTF3LkW2PFMh|ryPM1XLeXNCVkeHUh?=
BB65-RCCM2DUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPFW|VKSzVyPUG2MlAzPDFizszNNVLZdmR1W0GQR1XS
NCI-H1693NHLIWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn2[nJyUUN3ME2xOk4{QDB{IN88US=>MkXXV2FPT0WU
KARPAS-299MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTF4Lk[yNFMh|ryPM4jxTnNCVkeHUh?=
UACC-257M1:2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\vUWlEPTB;MUeuNFU5OiEQvF2=MYDTRW5ITVJ?
RKOMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTF5Lk[0N|Mh|ryPNH3QN4dUSU6JRWK=
HT-29M3\zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3DTWM2OD1zNz63PFg6KM7:TR?=MVjTRW5ITVJ?
ES7NX;ZeHY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zySmlEPTB;MUiuNVEzOiEQvF2=M{\Hb3NCVkeHUh?=
DELM{HKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvkZ2dKSzVyPUG4MlMyPzJizszNNIfQUJpUSU6JRWK=
BT-549Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIS1XFVKSzVyPUG4MlQxQTJizszNNFXyb2pUSU6JRWK=
NCI-H1755MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTV[pZ5UUN3ME2xPE42PzJ|IN88US=>MnvMV2FPT0WU
HCE-TMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jJbWlEPTB;MUiuPFM1OSEQvF2=Mn7lV2FPT0WU
LU-139NIP3flBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPxTWM2OD1zOT6wOFU5KM7:TR?=NXnJeJlFW0GQR1XS
ECC10M1nIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTJTWM2OD1zOT6yOFc2KM7:TR?=MUDTRW5ITVJ?
769-PNYruO3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{Hke2lEPTB;MUmuOlM{PSEQvF2=NVXRUnl7W0GQR1XS
BALL-1NHPwS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPmVnNKSzVyPUG5MlY4PzVizszNNY[2[3dzW0GQR1XS
LXF-289M4XrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF7Lki5O|kh|ryPMX;TRW5ITVJ?
TYK-nuNEfnZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTF7LkmzNVUh|ryPM4DJSXNCVkeHUh?=
NCI-H630NFq2WIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPiT4RKSzVyPUG5Mlk{PzhizszNMlntV2FPT0WU
EW-18NX\WUnFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnj0TWM2OD1{MD6zPFAzKM7:TR?=Mn7TV2FPT0WU
KYSE-150NUexZ442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13uRWlEPTB;MkCuO|A1PyEQvF2=M4rRS3NCVkeHUh?=
LOXIMVINIDQW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LJS2lEPTB;MkCuO|U5PiEQvF2=Mn3QV2FPT0WU
HuP-T3NF7zWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nxSGlEPTB;MkGuNFg2OiEQvF2=NEj0RY5USU6JRWK=
MFE-280NYT1UFRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{f0PWlEPTB;MkGuOVY4QSEQvF2=MXTTRW5ITVJ?
SK-OV-3NYTkUoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJzLki0NFgh|ryPMoflV2FPT0WU
QIMR-WILNFP3c2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHO5SlJKSzVyPUKyMlA1PzhizszNNVnB[m1DW0GQR1XS
NCI-H69NU\xZ3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3UcJJKSzVyPUKyMlQzQTlizszNNELZU4hUSU6JRWK=
TE-5M4HjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJ{LkS5OlUh|ryPNFzNS5FUSU6JRWK=
NCI-H1993MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTJ{LkS5O|Eh|ryPM3yz[3NCVkeHUh?=
NCI-H1092MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjOTWM2OD1{Mz6yPFQ{KM7:TR?=Mly2V2FPT0WU
RH-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTJ|LkWzOVch|ryPM1LvOXNCVkeHUh?=
DBTRG-05MGMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlT6TWM2OD1{Mz64OFczKM7:TR?=NGH1SGVUSU6JRWK=
Mo-TNUH6T3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrC[VZKSzVyPUKzMlkh|ryPNY\GZXVrW0GQR1XS
HD-MY-ZM{DtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\WRoRKSzVyPUK0MlI{PjJizszNNFLQfG5USU6JRWK=
NCI-H2342M1jkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v5U2lEPTB;MkSuOlc3PyEQvF2=MV7TRW5ITVJ?
C32NHHMNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJ2Lkm1O|Yh|ryPNIfMW|dUSU6JRWK=
HTC-C3MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWW2TGdSUUN3ME2yOU4{PTd5IN88US=>NWrScGNLW0GQR1XS
NCI-H358MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfzU5ZKSzVyPUK1MlM6PDNizszNMUHTRW5ITVJ?
CAL-85-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHzXpdKSzVyPUK1MlQ2PzdizszNMkX4V2FPT0WU
HT-1197MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MliyTWM2OD1{NT61N|E6KM7:TR?=M4rWeXNCVkeHUh?=
A172NVi3OYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXBcVhRUUN3ME2yOU44OTN4IN88US=>M2DQRXNCVkeHUh?=
SW1573M4LqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLRTWM2OD1{NT63O|g2KM7:TR?=M1rqNHNCVkeHUh?=
EW-24NFn5fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzwTWM2OD1{NT65OlIh|ryPMofvV2FPT0WU
SK-MEL-2NVLEe|k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrPTWM2OD1{Nj6wN|EzKM7:TR?=MV7TRW5ITVJ?
LU-65MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJ4LkC0OVIh|ryPNFPTfmpUSU6JRWK=
KMOE-2NFPsZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkj4TWM2OD1{Nj6wPVE2KM7:TR?=MUHTRW5ITVJ?
H-EMC-SSMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\nfmlEPTB;Mk[uOFEyPCEQvF2=M3zBPHNCVkeHUh?=
H4NGXFVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\1b2lEPTB;Mk[uOFI1OyEQvF2=M1vjOXNCVkeHUh?=
DU-4475NVnz[FR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvN[Ih3UUN3ME2yO{4yQDd{IN88US=>NH\Wc2tUSU6JRWK=
HCT-116M{PJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGn5d45KSzVyPUK3MlQ{PDlizszNNUPVZYNoW0GQR1XS
MSTO-211HMl3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HNVmlEPTB;MkeuOlI2PSEQvF2=NIHLO5BUSU6JRWK=
NCI-H292M1jrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3tSIdKSzVyPUK3Mlk3OTdizszNNXHv[nppW0GQR1XS
NCI-H446MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXzTWM2OD1{OD6yNVA2KM7:TR?=NETwVpJUSU6JRWK=
NCI-H2009MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2P3NWlEPTB;MkmuNVQ{OSEQvF2=NYHNNHNQW0GQR1XS
MHH-ES-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTJ7LkO2PFUh|ryPMnX2V2FPT0WU
TI-73MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoH0TWM2OD1{OT60NFAyKM7:TR?=NEfmSFZUSU6JRWK=
NCI-H2228NFrjNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2m2[WlEPTB;MkmuOFU5KM7:TR?=MknVV2FPT0WU
MHH-PREB-1M1zMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\LTWM2OD1{OT61OVA2KM7:TR?=NVjnZoNoW0GQR1XS
ChaGo-K-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3wTWM2OD1{OT62NFk4KM7:TR?=Mn7UV2FPT0WU
KY821NHTzUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEOzPFNKSzVyPUK5MlY1OzNizszNMYnTRW5ITVJ?
NCI-H209M3LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDoTWM2OD1{OT64N|Y3KM7:TR?=NXW3TG1VW0GQR1XS
NBsusSRM4\Kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVroZZZzUUN3ME2yPU46QTB2IN88US=>MVXTRW5ITVJ?
NCI-H1304M1TGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTNyLkW3NVYh|ryPNF[wRYtUSU6JRWK=
NB14NIDoenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nDWmlEPTB;M{GuNFQ1PiEQvF2=NYD3V5Q4W0GQR1XS
HCC1419MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrpXoFYUUN3ME2zNU4zPCEQvF2=NYLzOJFsW0GQR1XS
KG-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;GPWlEPTB;M{GuO|QzQSEQvF2=NHvhd5dUSU6JRWK=
A2780MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXVcYdJUUN3ME2zNU45OzV6IN88US=>NYm5TnZ[W0GQR1XS
NCI-H28MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTNzLkm4OlEh|ryPNIjiU5VUSU6JRWK=
C2BBe1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jIdGlEPTB;M{KuNlY{PCEQvF2=M3qzb3NCVkeHUh?=
VA-ES-BJNXHZVHVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfER2VoUUN3ME2zNk4{OSEQvF2=NVzaOXNwW0GQR1XS
SBC-5NXXxWotPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfjTWM2OD1|Mj64OVEyKM7:TR?=MmPUV2FPT0WU
OVCAR-4MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLMdYl7UUN3ME2zN{41QDR6IN88US=>NXn4cHVGW0GQR1XS
COR-L88NH\0dIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4C0RmlEPTB;M{SuNFc1OSEQvF2=M4fSVnNCVkeHUh?=
SW954M3\pOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTN2LkC3OVIh|ryPNYKyWXdRW0GQR1XS
COLO-684NH\ZZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHOOmU1UUN3ME2zOE4{PDB2IN88US=>NYjkUJJjW0GQR1XS
HCC70NWn0Wm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmS1TWM2OD1|ND65OVE1KM7:TR?=M3TTZ3NCVkeHUh?=
NCI-H1770NEn1Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHUTWM2OD1|ND65OlEh|ryPMX3TRW5ITVJ?
NCI-H1666Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LQemlEPTB;M{WuPFI2OyEQvF2=NGnGWXNUSU6JRWK=
YH-13MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTN3LkmyJO69VQ>?NXTHb4s6W0GQR1XS
DJM-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnQPHJRUUN3ME2zOk45ODR7IN88US=>Mn7TV2FPT0WU
KNS-62M4jabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfRNIZKSzVyPUO2Mlk1OzhizszNMoH4V2FPT0WU
SK-MEL-30NYDvbWFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHyZXpKSzVyPUO3Mlg4OzdizszNMnzJV2FPT0WU
SJRH30MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHkbXRNUUN3ME2zPE44OzRzIN88US=>MliwV2FPT0WU
GP5dMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTN6Lki2OVMh|ryPMUHTRW5ITVJ?
SW1116NEKzdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfaTWM2OD1|OT6yPFA2KM7:TR?=Ml\SV2FPT0WU
COLO-800M2O2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPZTWM2OD1|OT6zOlM5KM7:TR?=MUTTRW5ITVJ?
RDNFPMR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3joOGlEPTB;M{muOVI2QCEQvF2=NYizelNJW0GQR1XS
NCI-SNU-5M4\DWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoSzTWM2OD1|OT62PVE3KM7:TR?=NVjYT5U2W0GQR1XS
HuO-3N1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnyR2xNUUN3ME20NE4yODhizszNNFX6e2RUSU6JRWK=
SK-UT-1NWfneYlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrqT|BHUUN3ME20NE42Pjd2IN88US=>M2Trd3NCVkeHUh?=
SK-MEL-3NXT3ZVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jGeWlEPTB;NECuOVk{OiEQvF2=NVi0RppNW0GQR1XS
SK-MEL-28M1z6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTRyLk[0N|Uh|ryPNUToPXhHW0GQR1XS
SCC-4MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PYcmlEPTB;NEGuNlE{PyEQvF2=MXnTRW5ITVJ?
no-11MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYL0UJU6UUN3ME20NU44OzV2IN88US=>M1nnc3NCVkeHUh?=
HT-144MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfBTWM2OD12Mj6wOVY4KM7:TR?=NHz1[HRUSU6JRWK=
MFM-223NG\lTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TzbWlEPTB;NEKuOFAzKM7:TR?=MkHjV2FPT0WU
ONS-76NFm1XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTjTldbUUN3ME20Nk45ODF6IN88US=>MVnTRW5ITVJ?
ES8M2L3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\qTWM2OD12Mz6zOlk5KM7:TR?=NY[5dGJmW0GQR1XS
T-24MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTR|LkSzOlkh|ryPMVfTRW5ITVJ?
GAMGNIm4[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkC0TWM2OD12Mz60OVE4KM7:TR?=NGLDWlVUSU6JRWK=
LU-135M2e3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXFPGJKSzVyPUS0MlA6OjNizszNM{jjW3NCVkeHUh?=
HCC1187NFrVfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[2TWM2OD12ND64NlYzKM7:TR?=M3LZVHNCVkeHUh?=
TE-1MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vFbmlEPTB;NEWuNVY2PCEQvF2=MYjTRW5ITVJ?
J-RT3-T3-5NFf4S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTR3LkSzNVUh|ryPNXPW[41HW0GQR1XS
GI-ME-NNHTTPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUG4bW14UUN3ME20OU45QTV{IN88US=>MYjTRW5ITVJ?
D-392MGNG\vOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEW5dJRKSzVyPUS1MlkzPTZizszNM4PVbHNCVkeHUh?=
KALS-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHiToxKSzVyPUS2MlczPTdizszNMlnvV2FPT0WU
MMAC-SFMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zOTWlEPTB;NE[uPVk2OiEQvF2=NFf3bYFUSU6JRWK=
HSC-3NUPqXIs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTzTWM2OD12Nz6zOlA5KM7:TR?=M{PGcHNCVkeHUh?=
KM-H2Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHIVVV5UUN3ME20O{43ODB5IN88US=>NHu5TGRUSU6JRWK=
LoVoM3nhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\OTWM2OD12OD6xNFAzKM7:TR?=NVXVcVJ2W0GQR1XS
NCI-H510ANUT6OVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfFTWM2OD12OD6xPFcyKM7:TR?=NYL4UXV5W0GQR1XS
EW-11MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWP3RlRqUUN3ME20PE4zOzR6IN88US=>NGLhVGVUSU6JRWK=
HCC2998NF3wOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;CdWlEPTB;NEiuOlI{PiEQvF2=NHTVWGxUSU6JRWK=
J82NIL5bmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPQTWM2OD12OD63NlQzKM7:TR?=M2DSR3NCVkeHUh?=
ML-2M1ewdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLaTWM2OD12OT60OlA2KM7:TR?=MoHXV2FPT0WU
NCI-H2030NUjydVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmm4TWM2OD12OT63NVE4KM7:TR?=MYjTRW5ITVJ?
NCI-H1792MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLFc5hKSzVyPUS5Mlg2OThizszNM17xR3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]
Features A selective inhibitor of native and mutant Bcr-Abl.

Protocol(Only for Reference)

Cell Assay: [4]

Cell lines Human primary Schwann and schwannoma cells
Concentrations 1-10 μM
Incubation Time 72 hours
Method Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.

Animal Study: [6]

Animal Models Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
Formulation 10% NMP-90% PEG300, PEG300
Dosages 75 mg/kg, 100 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Weisberg E, et al. Blood. 2007, 109(5), 2112-2120.

[2] Liu Y, et al. J Hepatol. 2011, 55(3), 612-625.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Emory University May 2016 Phase 2
NCT02602314 Not yet recruiting Chronyc Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto March 2016 Phase 4
NCT02546674 Recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis February 2016 Phase 4
NCT02627677 Recruiting Chronic Phase Chronic Myeloid Leukemia Ariad Pharmaceuticals December 2015 Phase 3
NCT02733445 Completed Chronic Myeloid Leukemia (CML) Bristol-Myers Squibb December 2015 --

view more

Chemical Information

Download Nilotinib (AMN-107) SDF
Molecular Weight (MW) 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 27 mg/mL (50.98 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO/30% PEG 300/5% Tween 80/ddH2O 3mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Customer Product Validation (5)


Click to enlarge
Rating
Source FASEB J 2011 25, 3661-3673. Nilotinib (AMN-107) purchased from Selleck
Method Analyzing cell apoptosis
Cell Lines Ba/F3-p210T315I cells
Concentrations 0-5 μM
Incubation Time 24 h
Results In a parallel study using imatinib/PDMP or nilotinib/PDMP combinations, to our surprise, similar significant synergy in Ba/F3-p210T315I cells was observed.

Click to enlarge
Rating
Source Molecules 2014 19, 3356-75. Nilotinib (AMN-107) purchased from Selleck
Method Western blot
Cell Lines K562, CD34+CD38- cells
Concentrations 0, 0.01, 0.1, 1 uM
Incubation Time 12 h
Results Since nilotinib targets the Bcr-Abl kinase in CML cells, we evaluated its ability to inhibit kinase activity in ABCB1- and ABCG2-overexpressing CD34+CD38- cells. In K562 cells, nilotinib effectively inhibited the phosphorylation of Bcr-Abl and CrkL (a surrogate marker of Bcr-Abl activity) at a concentration of 0.1 umol/L. However, in CD34+CD38- cells, nilotinib failed to completely inhibit the phosphorylation of Bcr-Abl and CrkL even when cells were exposed to concentration up to 1.0 umol/L.

Click to enlarge
Rating
Source Leukemia Res 2012 36, 1311-1314. Nilotinib (AMN-107) purchased from Selleck
Method Thymidine uptake Uptake assay
Cell Lines K562, MEG-01 cells
Concentrations 0.1-10uM
Incubation Time 20 min
Results Nilotinib was much more potent than imatinib to inhibit nucleoside transport. It prevented the uptake of thymidine in K562 cells by 97% at 10 uM, a level that was similar to the one obtained with the vasodilatator molecule dipyridamole. Nilotinib was also very efficient at 1 and 0.1 uM; it blocked the entry of thymidine by 90 and 74%, respectively (Fig. 2a). With the MEG-01 cell line, nilotinib was also extremely potent and blocked the entry of thymidine by 96, 92 and 60% with 10, 1 and 0.1 uM nilotinib, respectively (Fig. 2b).

Click to enlarge
Rating
Source Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck
Method Immunoblot analyses
Cell Lines LNCaP, PC-3, DU-145 cells
Concentrations 10 uM
Incubation Time 24 h
Results It shows a robust overexpression of phospho-ERK1/2 T202/Y204 in nilotinib-treated DU-145 cells (B). An up-regulation of phospho-ERK1/2 T202/Y204 was also detectable in nilotinib-treated LNCaP cells, albeit at a lower level, and was not found in PC-3 cells (C).

Click to enlarge
Rating
Source Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Xenografted DU-145 cells
Concentrations 5 mg/kg/d
Incubation Time 21 days
Results Accoding to published animals experiments, DU-145 xenografts from a representative experiment in which nilotinib was used at a 75-mg/kg/d concentration. It's found a significant increase of phospho-ERK-positive residual tumor cells from a mean of 67.5 cells per high-powerfield in controls to 131.1 cells per high-powerfield in DU-145 xenografts treated for 21 days with nilotinib (P< 0.0005).

Product Use Citation (18)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcr-Abl Products

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

  • Ponatinib (AP24534)

    Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

  • Bafetinib (INNO-406)

    Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

    Features:Dual Bcr-Abl/Lyn inhibitor.

  • Degrasyn (WP1130)

    Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

    Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.

  • DCC-2036 (Rebastinib)

    DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

    Features:A conformational control inhibitor of Abl1 and T315I Abl1.

  • GZD824 Dimesylate

    GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

  • GNF-2

    GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Recently Viewed Items

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107) price | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) solubility dmso | Nilotinib (AMN-107) purchase | Nilotinib (AMN-107) manufacturer | Nilotinib (AMN-107) research buy | Nilotinib (AMN-107) order | Nilotinib (AMN-107) mouse | Nilotinib (AMN-107) chemical structure | Nilotinib (AMN-107) mw | Nilotinib (AMN-107) molecular weight | Nilotinib (AMN-107) datasheet | Nilotinib (AMN-107) supplier | Nilotinib (AMN-107) in vitro | Nilotinib (AMN-107) cell line | Nilotinib (AMN-107) concentration | Nilotinib (AMN-107) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us